

Linda R Duska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6643952/publications.pdf>

Version: 2024-02-01

46
papers

1,056
citations

567281

15
h-index

434195

31
g-index

48
all docs

48
docs citations

48
times ranked

1882
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Uterine carcinosarcoma: A review of the literature. <i>Gynecologic Oncology</i> , 2015, 137, 581-588. | 1.4 | 167 |
| 2 | Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 957-968. | 10.7 | 140 |
| 3 | When "never-events"™ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. <i>Gynecologic Oncology</i> , 2010, 116, 374-377. | 1.4 | 111 |
| 4 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097. | 4.5 | 82 |
| 5 | Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457. | 7.0 | 52 |
| 6 | Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. <i>Cancer</i> , 2020, 126, 4948-4956. | 4.1 | 37 |
| 7 | Histologic Effects of Medroxyprogesterone Acetate on Endometrioid Endometrial Adenocarcinoma. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 543-553. | 1.4 | 34 |
| 8 | Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). <i>Cancer</i> , 2017, 123, 977-984. | 4.1 | 31 |
| 9 | Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. <i>Modern Pathology</i> , 2020, 33, 1182-1192. | 5.5 | 28 |
| 10 | Lean methodology improves efficiency in outpatient academic Gynecologic Oncology clinics. <i>Gynecologic Oncology</i> , 2015, 138, 707-711. | 1.4 | 27 |
| 11 | Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. <i>Gynecologic Oncology</i> , 2017, 146, 34-38. | 1.4 | 27 |
| 12 | Are ethnic and racial minority women less likely to participate in clinical trials?. <i>Gynecologic Oncology</i> , 2020, 157, 323-328. | 1.4 | 27 |
| 13 | Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233. | | 24 |
| 14 | Strategies for Introducing Outpatient Specialty Palliative Care in Gynecologic Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, e712-e720. | 2.5 | 21 |
| 15 | Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). <i>Gynecologic Oncology</i> , 2015, 139, 221-227. | 1.4 | 20 |
| 16 | Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1184-1191. | 3.7 | 18 |
| 17 | A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 44-48. | 1.4 | 16 |
| 18 | Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse. <i>Gynecologic Oncology</i> , 2017, 147, 456-459. | 1.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Opioid Use in Gynecologic Oncology; Balancing Efficacy, Accessibility and Safety: An SGO Clinical Practice Statement. <i>Gynecologic Oncology</i> , 2017, 144, 232-234. | 1.4 | 15 |
| 20 | Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. <i>Gynecologic Oncology</i> , 2018, 149, 442-446. | 1.4 | 14 |
| 21 | Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers. <i>Gynecologic Oncology</i> , 2018, 150, 338-342. | 1.4 | 13 |
| 22 | Emerging biomarkers in ovarian granulosa cell tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 560-565. | 2.5 | 13 |
| 23 | Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.. <i>Gynecologic Oncology</i> , 2020, 157, 754-758. | 1.4 | 13 |
| 24 | Cancer Screening and Prevention Highlights in Gynecologic Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 19-36. | 1.9 | 11 |
| 25 | Treatment of Older Women With Endometrial Cancer: Improving Outcomes With Personalized Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 164-174. | 3.8 | 10 |
| 26 | Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review. <i>Gynecologic Oncology</i> , 2018, 149, 394-400. | 1.4 | 10 |
| 27 | Severe Gastrointestinal Complications in the Era of Image-guided High-dose-rate Intracavitary Brachytherapy for Cervical Cancer. <i>Clinical Therapeutics</i> , 2015, 37, 49-60. | 2.5 | 9 |
| 28 | A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2020, 156, 13-22. | 1.4 | 9 |
| 29 | Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II " Balancing safety & accessibility. <i>Gynecologic Oncology</i> , 2018, 149, 401-409. | 1.4 | 7 |
| 30 | A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 473-482. | 2.3 | 7 |
| 31 | A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. <i>Clinical Cancer Research</i> , 2021, 27, 2734-2741. | 7.0 | 7 |
| 32 | Preoperative imaging of uterine malignancy: A low-value service. <i>Gynecologic Oncology</i> , 2015, 137, 285-290. | 1.4 | 6 |
| 33 | Improving quality of life in female cancer survivors: current status and future questions. <i>Future Oncology</i> , 2014, 10, 1015-1026. | 2.4 | 4 |
| 34 | Nutrition in Gynecologic Cancer. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 265-271. | 0.8 | 4 |
| 35 | Access to quality gynecologic oncology care: A work in progress. <i>Cancer</i> , 2018, 124, 2680-2683. | 4.1 | 4 |
| 36 | Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success. <i>Gynecologic Oncology</i> , 2021, 160, 271-278. | 1.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 512-515. | 1.4 | 4 |
| 38 | Cervical Cancer: The Next Generation of Prevention, Detection, and Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 446-448. | 2.5 | 3 |
| 39 | The Patient Protection and Affordable Care Act: What every provider of Gynecologic Oncology care should know. <i>Gynecologic Oncology</i> , 2013, 129, 606-612. | 1.4 | 2 |
| 40 | Targeted Therapies and Immunotherapy for Gynecologic Malignancies: Living Longer, Living Better With Noncytotoxic Options in Recurrent Disease. <i>Clinical Therapeutics</i> , 2018, 40, 358-360. | 2.5 | 2 |
| 41 | Prevention of human papillomavirus-related malignancy: Access is the answer. <i>Cancer</i> , 2013, 119, 2953-2955. | 4.1 | 1 |
| 42 | Fertility-Sparing Options for Early Cervical Cancer: Optimism for Oncologic and Obstetric Outcomes. <i>Current Obstetrics and Gynecology Reports</i> , 2016, 5, 296-306. | 0.8 | 1 |
| 43 | Cutting costs and standardizing care: Once-per-cycle complete blood count monitoring may be safe for patients undergoing platinum-based chemotherapy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 758-762. | 1.3 | 1 |
| 44 | The role of pulmonary resection in the management of metastatic gestational trophoblastic neoplasia: Two cases of durable remission following surgery for chemo-resistant disease. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100496. | 0.6 | 1 |
| 45 | Does one size fit all? The updated ovarian cancer staging: Still a work in progress. <i>Cancer</i> , 2015, 121, 3384-3386. | 4.1 | 0 |
| 46 | A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule ROR γ agonist to treat select solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS2617-TPS2617. | 1.6 | 0 |